Safety and Efficacy of Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients; Prospective Cohort

2012 ◽  
Vol 94 (10S) ◽  
pp. 913
Author(s):  
H. A. Al Eid ◽  
K. Bzeizi ◽  
D. Mousa ◽  
H. Alashgar ◽  
K. Al Meshari ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Chronic Hepatitis C ◽  
Combination Treatment ◽  
Prospective Cohort ◽  
Safety And Efficacy ◽  
Transplant Patients ◽  
Renal Transplant Patients ◽  
Peginterferon Alfa

Serological Markers of Autoimmunity in Renal Transplant Patients with Chronic Hepatitis C

1998 ◽  
Vol 18 (1) ◽  
pp. 50-56 ◽  
Author(s):  
Lionel Rostaing ◽  
Anne Modesto ◽  
Jean Marc Cisterne ◽  
Jacques Izopet ◽  
Françoise Oksman ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Chronic Hepatitis C ◽  
Serological Markers ◽  
Transplant Patients ◽  
Renal Transplant Patients

Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C

2005 ◽  
Vol 76 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Nassim Kamar ◽  
Anne Boulestin ◽  
Janick Selves ◽  
Laure Esposito ◽  
Karine Sandres-Saune ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Fibrosis Progression ◽  
Transplant Patients ◽  
Renal Transplant Patients

Serological Markers of Autoimmunity in Renal Transplant Patients before and after Alpha-interferon Therapy for Chronic Hepatitis C

1996 ◽  
Vol 16 (6) ◽  
pp. 478-483 ◽  
Author(s):  
Lionel Rostaing ◽  
Françoise Oksman ◽  
Jacques Izopet ◽  
Emmanuel Baron ◽  
Jean-Marc Cisterne ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Chronic Hepatitis C ◽  
Interferon Therapy ◽  
Alpha Interferon ◽  
Serological Markers ◽  
Transplant Patients ◽  
Before And After ◽  
Renal Transplant Patients

Diagnostic Accuracy of the Fibrotest in Hemodialysis and Renal Transplant Patients with Chronic Hepatitis C Virus

2005 ◽  
Vol 80 (11) ◽  
pp. 1550-1555 ◽  
Author(s):  
Anne Varaut ◽  
Helene Fontaine ◽  
Jeanne Serpaggi ◽  
Virginie Verkarre ◽  
Anais Vallet-Pichard ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Diagnostic Accuracy ◽  
Chronic Hepatitis C ◽  
Transplant Patients ◽  
Chronic Hepatitis C Virus ◽  
Renal Transplant Patients

Changing pattern of chronic hepatitis C in renal transplant patients over 20 years

2019 ◽  
Vol 31 (9) ◽  
pp. 1141-1147 ◽  
Author(s):  
Christini T. Emori ◽  
Sílvia N.O. Uehara ◽  
Roberto J. Carvalho-Filho ◽  
Ana Cristina Amaral ◽  
Ivonete S. de Souza e Silva ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Chronic Hepatitis C ◽  
Transplant Patients ◽  
Renal Transplant Patients

scholarly journals Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

2018 ◽  
Vol 6 ◽  
pp. 205031211878141 ◽  
Author(s):  
Mete Akin ◽  
Osman Cagin Buldukoglu ◽  
Haydar Adanir ◽  
Inci Suleymanlar ◽  
Dinc Dincer ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Renal Transplantation ◽  
Hepatitis C ◽  
Renal Transplant ◽  
Adverse Effects ◽  
Liver Transplant ◽  
Chronic Hepatitis C ◽  
Solid Organ ◽  
Transplant Patients ◽  
Renal Transplant Patients

Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C were evaluated. Materials and methods: A total of 23 liver and/or renal transplant patients who received sofosbuvir/ledipasvir ± ribavirin for chronic hepatitis C over 12 or 24 weeks were enrolled in the study. The treatment response, clinical and laboratory adverse effects, and effect on immunosuppressive drug levels were assessed. Results: A total of 12 patients had undergone renal transplantation and 11 had undergone liver transplantation. All of the renal transplant patients and 91% of liver transplant patients had genotype 1. In total, 10 renal transplant patients and 4 liver transplant patients had treatment experience. Two renal transplant patients and one liver transplant patient had compensated cirrhosis. Nine renal transplant patients were on tacrolimus, and two were on cyclosporine; all of the liver transplant patients were on tacrolimus-based immunosuppressive therapy. While hepatitis C RNA was negative in 75% of renal transplant patients and 91% of liver transplant patients at week 4, it was negative in all of the patients at the end of treatment and 12 weeks after treatment. Significantly reduced hemoglobin levels were observed in patients administered ribavirin during treatment (p = 0.01). There were no significant differences between the baseline and treatment period values of mean creatinine, estimated glomerular filtration rate, bilirubin, and tacrolimus levels. There were no adverse effects leading to treatment discontinuation. Conclusion: Sofosbuvir/ledipasvir ± ribavirin is quite safe and effective in hepatitis C treatment after liver and/or renal transplantation.

Sign in / Sign up

Export Citation Format

Share Document